Christopher J C Marriott1,2, Lesley F Beaumont2, Troy H Farncombe1,2, Amy N Cranston3, Uma H Athale3,4, Valerie N Yakemchuk1,2, Colin E Webber1,2, Ronald D Barr3,4,5,6. 1. Department of Radiology, McMaster University, Hamilton, Ontario, Canada. 2. Department of Nuclear Medicine, Hamilton Health Sciences and St. Joseph's Hospital, Hamilton, Ontario, Canada. 3. Division of Hematology-Oncology, McMaster Children's Hospital, Hamilton, Ontario, Canada. 4. Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. 5. Department of Pathology, McMaster University, Hamilton, Ontario, Canada. 6. Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The late effects of treatment for acute lymphoblastic leukemia (ALL) include disordered body composition, especially obesity. Less attention has been focused on the loss of skeletal muscle mass (SMM) and the combined morbidity of sarcopenic obesity. METHODS: A cross-sectional study of body composition was undertaken via dual-energy x-ray absorptiometry in 75 long-term survivors of ALL (more than 10 years after the diagnosis). Measures were obtained of the fat mass (FM), fat-free mass (equivalent to the lean body mass [LBM]), and whole-body bone mineral content. Health-related quality of life (HRQL) was measured with the Health Utilities Index. RESULTS: The sum of the FM, LBM, and whole-body bone mineral content matched the total body weight measured directly (r = 0.998). The appendicular lean mass (ALM) was derived from the LBM in all 4 limbs and accounted for approximately 75% of the SMM. According to the fat mass index (FMI; ie, FM/height2 ), 12% of females and 18% of males were frankly obese by World Health Organization criteria. The median FMI z score was + 0.40, whereas the median z score for the appendicular lean mass index (ALMI; ie, ALM/height2 ) was -0.40. Sarcopenic obesity, defined as a positive FMI z score with a negative ALMI z score, was present in 32 subjects (43%). There were statistically significant and clinically important differences in overall HRQL between subjects with and without sarcopenic obesity. CONCLUSIONS: Sarcopenic obesity is prevalent in long-term survivors of ALL, and this places them in double jeopardy from excess body fat and inadequate SMM (eg, a combination of metabolic and frailty syndromes). It is associated with an adverse impact on overall HRQL. Cancer 2018;124:1225-31.
BACKGROUND: The late effects of treatment for acute lymphoblastic leukemia (ALL) include disordered body composition, especially obesity. Less attention has been focused on the loss of skeletal muscle mass (SMM) and the combined morbidity of sarcopenic obesity. METHODS: A cross-sectional study of body composition was undertaken via dual-energy x-ray absorptiometry in 75 long-term survivors of ALL (more than 10 years after the diagnosis). Measures were obtained of the fat mass (FM), fat-free mass (equivalent to the lean body mass [LBM]), and whole-body bone mineral content. Health-related quality of life (HRQL) was measured with the Health Utilities Index. RESULTS: The sum of the FM, LBM, and whole-body bone mineral content matched the total body weight measured directly (r = 0.998). The appendicular lean mass (ALM) was derived from the LBM in all 4 limbs and accounted for approximately 75% of the SMM. According to the fat mass index (FMI; ie, FM/height2 ), 12% of females and 18% of males were frankly obese by World Health Organization criteria. The median FMI z score was + 0.40, whereas the median z score for the appendicular lean mass index (ALMI; ie, ALM/height2 ) was -0.40. Sarcopenic obesity, defined as a positive FMI z score with a negative ALMI z score, was present in 32 subjects (43%). There were statistically significant and clinically important differences in overall HRQL between subjects with and without sarcopenic obesity. CONCLUSIONS:Sarcopenic obesity is prevalent in long-term survivors of ALL, and this places them in double jeopardy from excess body fat and inadequate SMM (eg, a combination of metabolic and frailty syndromes). It is associated with an adverse impact on overall HRQL. Cancer 2018;124:1225-31.
Authors: Nguyen K Tram; Ting-Heng Chou; Laila N Ettefagh; Kyra Deep; Adam J Bobbey; Anthony N Audino; Mitchel R Stacy Journal: Eur Radiol Date: 2022-08-10 Impact factor: 7.034
Authors: Brianna R Murphy; Margaret P Raber; Karla D Crawford; Leslie Grasse; Lisa Wartenberg; Jimin Wu; Seyedeh S Dibaj; Joya Chandra Journal: Child Obes Date: 2020-03-13 Impact factor: 2.992
Authors: Carolina Simioni; Giorgio Zauli; Alberto M Martelli; Marco Vitale; Simona Ultimo; Daniela Milani; Luca M Neri Journal: Oncotarget Date: 2018-03-30